Ginkgo Bioworks Holdings (DNA): government contracts, filings & geopolitical news
Ginkgo Bioworks Holdings (DNA) and its matched subsidiaries received $28.8M in federal contract obligations in the last 12 months and $100.0M over the last five years, according to USAspending.gov. The Department of Health and Human Services accounted for 95% of the five-year total, followed by the Department of Defense (5%). Annual obligations rose from $4.0M in fiscal 2025 to $28.8M in fiscal 2026 (+617%). Its largest contract with activity in that period is 75D30125C20439 from the Centers for Disease Control and Prevention for traveler-based genomic surveillance program, with $78.0M obligated over the life of the award. 1 tracked superinvestor portfolio reported DNA in the latest 13F filings.
Ginkgo Bioworks Holdings government contracts
Obligations by agency
| Agency | Last 12 months | Last 5 years | Share of 5 years |
|---|---|---|---|
| Department of Health and Human Services | $28.8M | $95.2M | 95% |
| Department of Defense | $0 | $4.8M | 5% |
Top contracting offices (5 years): Centers for Disease Control and Prevention $95.2M; Defense Advanced Research Projects Agency $4.6M; Department of the Army $368K; Department of the Navy -$135K.
Largest contracts
| Award | Description · recipient | Agency | Obligated (award total) | Start | End |
|---|---|---|---|---|---|
| 75D30125C20439 | Traveler-based genomic surveillance program GINKGO BIOWORKS, INC. | Department of Health and Human Services Centers for Disease Control and Prevention | $78.0M | Feb 28, 2025 | Mar 21, 2028 |
| 75D30122C14933 | Airport genomic testing GINKGO BIOWORKS, INC. | Department of Health and Human Services Centers for Disease Control and Prevention | $62.6M | Aug 16, 2022 | Mar 21, 2025 |
| HR001124C0378 | Darpa ice control for cold environments (ice) GINKGO BIOWORKS, INC. | Department of Defense Defense Advanced Research Projects Agency | $5.2M | Jan 26, 2024 | Aug 19, 2026 |
| W911NF23C0002 | Darpa contract award (base) "superb: synbio + universal purification of extract-derived, right-on-time biologics" GINKGO BIOWORKS, INC. | Department of Defense Department of the Army | $4.8M | Dec 15, 2022 | Feb 29, 2024 |
| 75D30124F00001 | Test surge and data sharing multiple award idiq GINKGO BIOWORKS, INC. | Department of Health and Human Services Centers for Disease Control and Prevention | $3.8M | Sep 6, 2024 | Sep 5, 2027 |
| 75D30126F00004 | Metagenomic next-generation sequencing (mngs) GINKGO BIOWORKS, INC. | Department of Health and Human Services Centers for Disease Control and Prevention | $3.2M | May 3, 2026 | Apr 14, 2028 |
| N6600123C4509 | Dna recording intrinsic cellular biointelligence (drinc bio) GINKGO BIOWORKS, INC. | Department of Defense Department of the Navy | $1.8M | May 2, 2023 | May 21, 2025 |
| 75D30124C19895 | Traveler-based genomic surveillance GINKGO BIOWORKS, INC. | Department of Health and Human Services Centers for Disease Control and Prevention | $1.2M | Aug 26, 2024 | Sep 19, 2024 |
| 75D30124F00002 | Test surge and data sharing multiple award idiq GINKGO BIOWORKS, INC. | Department of Health and Human Services Centers for Disease Control and Prevention | $775K | Sep 27, 2024 | Sep 26, 2025 |
| 75D30125F00003 | Test surge and data sharing multiple award idiq GINKGO BIOWORKS, INC. | Department of Health and Human Services Centers for Disease Control and Prevention | $450K | Jan 16, 2025 | May 15, 2025 |
Newest contracts
| Award | Description · recipient | Agency | Obligated (award total) | Start | End |
|---|---|---|---|---|---|
| 75D30126F00004 | Metagenomic next-generation sequencing (mngs) GINKGO BIOWORKS, INC. | Department of Health and Human Services Centers for Disease Control and Prevention | $3.2M | May 3, 2026 | Apr 14, 2028 |
| 75D30125C20439 | Traveler-based genomic surveillance program GINKGO BIOWORKS, INC. | Department of Health and Human Services Centers for Disease Control and Prevention | $78.0M | Feb 28, 2025 | Mar 21, 2028 |
| 75D30124F00001 | Test surge and data sharing multiple award idiq GINKGO BIOWORKS, INC. | Department of Health and Human Services Centers for Disease Control and Prevention | $3.8M | Sep 6, 2024 | Sep 5, 2027 |
Matched USAspending recipients: GINKGO BIOWORKS HOLDINGS, INC. (UEI V62PM6L4HV34, parent with subsidiaries).
Contract data: USAspending.gov (federal prime contract obligations, award types A-D, by action date) and the Department of Defense daily contract announcements (awards of $7.5 million or more). Both are public-domain U.S. government data. Company matching uses legal names and parent/child recipient records and is deliberately conservative, so some subsidiaries may be missing. Obligations are not revenue. Not investment advice.
DNA share price, last 12 months
Close $7.89 on Jun 12, 2026, -41.9% since Oct 24, 2025 (range $5.48 to $13.57, daily closes).
Company facts
- Ticker
- DNA (NYSE)
- Sector
- Health
- Industry (SEC SIC code)
- Biological Products, (No Diagnostic Substances) (2836)
Industry from the SEC Standard Industrial Classification code on the company's EDGAR filings.
What changed for Ginkgo Bioworks Holdings (DNA)
- 0 news
- 0 SEC filings
- 0 fund / insider trades
Latest SEC filings
None on record yet.
Latest fund & insider buys and sales
None on record yet.
Held by superinvestors
1 of the tracked billionaire portfolios reported DNA in their latest 13F. 13F data is delayed up to 45 days after quarter end; not advice.
| Manager | % of portfolio | Value | Change | Quarter |
|---|---|---|---|---|
| Andreas Halvorsen Viking Global Investors | 0.10% | $35.4M | No change | Q2 2026 |
Latest geopolitical & market news
None on record yet.
Peers: Biological Products, (No Diagnostic Substances)
| Company | Ticker | Federal contracts, 12 months |
|---|---|---|
| Amgen | AMGN | $126.0M |
| Gilead Sciences | GILD | – |
| Moderna | MRNA | – |
| argenx SE | ARGX | – |
| Revolution Medicines | RVMD | – |
| Biogen | BIIB | – |
| BioNTech SE | BNTX | – |
| Exelixis | EXEL | – |
| Neurocrine Biosciences | NBIX | – |
| Halozyme Therapeutics | HALO | – |
Biggest government contractors in Health: Regeneron Pharmaceuticals ($279.4M), Fresenius Medical Care AG ($236.7M), Emergent BioSolutions ($216.6M), DaVita ($154.5M), Abbott Laboratories ($147.5M), Amgen ($126.0M), Labcorp Holdings ($96.4M), Stryker ($92.5M).
Congressional trades in DNA
Trades in DNA that members of Congress have publicly reported, newest filing first.
No congressional trades are stored for this view yet.
All congressional stock trades →
Geopolitical news for DNA
Everything on DNA, newest first
No original notes are listed on this page yet.
Frequently asked questions
How much does the U.S. government spend with Ginkgo Bioworks Holdings?
USAspending.gov shows $28.8M in federal contract obligations to Ginkgo Bioworks Holdings (DNA) and its matched subsidiaries in the last 12 months and $100.0M over the last five years (as of Oct 28, 2026).
Which agencies award contracts to Ginkgo Bioworks Holdings?
Over five years: Department of Health and Human Services $95.2M; Department of Defense $4.8M.
Where does the contract data come from?
USAspending.gov (the official source of U.S. federal spending data) and the Department of Defense's daily contract announcements. Both are public domain and refreshed daily here.
What geopolitical news affects DNA?
This page lists every Geopolitics Alpha note that names DNA as exposed to an event, with the reason it is exposed.
Has Congress traded DNA?
The table above lists trades in DNA that members of Congress have publicly reported, with a link to each official filing.
Is this investment advice?
No. We show news, exposure and past price moves. Nothing here is a recommendation.